BCG疫苗接种与老年人系统性eicosanoid水平的纵向变化有关:二次结果分析
Pavan Kumar Nathella1, Chandrasekaran Padmapriyadarsini1, Arul Nancy2
1ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Heliyon
|July 8, 2024
概括
BCG疫苗接种通过改变eicosanoid水平来调节老年人的免疫反应. 它减少了15-epi-LXA4和PGE2等炎症媒介,同时增加了Leukotriene B4 (LTB4).
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 代谢学 代谢学 代谢学
背景情况:
- 卡尔梅特 - 格林杆菌 (BCG) 疫苗以其广泛的免疫调节作用而闻名,除了预防结核病之外.
- 老年人群表现出改变的免疫反应,可能受益于加强免疫监测的疫苗.
- 伊可索诺伊德在调节炎症和免疫细胞功能方面发挥着至关重要的作用.
研究的目的:
- 研究BCG疫苗接种对健康老年人的血eicosanoid概况的影响.
- 评估特定eicosanoids的变化,包括Leukotriene B4 (LTB4),Lipoxin A4 (15-epi-LXA4) 的15-epimer,Lipoxin A4 (LXA4),Prostaglandin E2 (PGE2),Prostaglandin F2 (PGF2) 和Resolvin D1 (RvD1) 的变化.
- 了解BCG疫苗接种在临床试验中对老年人COVID-19影响的免疫结果.
主要方法:
- 在BCG接种疫苗之前,接种疫苗后一个月 (M1) 和接种疫苗后六个月 (M6) 从健康的老年人 (60-80岁) 收集血样本.
- 特定的eicosanoids (LTB4,15-epi-LXA4,PGF2,LXA4,PGE2,RvD1) 的水平使用验证的测试来量化.
- 进行了统计分析,以确定疫苗接种后eicosanoid水平的显著变化.
主要成果:
- 接种BCG疫苗显著降低了M1和M6.2的15-epi-LXA4,LXA4,PGE2和RvD1的血水平.
- 在BCG疫苗接种后,M1和M6的LTB4循环水平显著增加.
- 前列腺素F2水平在BCG疫苗接种后的反应中没有显著变化.
结论:
- 在老年人中,BCG疫苗接种通过改变eicosanoid配置文件来产生免疫调节作用.
- 观察到的促炎性eicosanoids的减少表明潜在的抑制炎症反应.
- 增加的LTB4水平可能表明转向特定的免疫细胞激活通路,需要进一步调查.
相关概念视频
02:20Longitudinal Research
11.7K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
11.7K
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
868
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
868
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
387
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
387
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
405
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
405
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
358
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
358
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
376
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
376